ANGPTL3 and diabetes mellitus: In a double-blind placebo-controlled dose-ranging phase 2 study, vupanorsen, an siRNA targeted to liver ANGPTL3, was evaluated in 105 patients with symptoms of triglyceridemia, diabetes and steatohepatitis [21].